Drugs · Brain health technique
Rapamycin / Everolimus
Evidence grade: Experimental
Drugs that inhibit the mTOR (mechanistic target of rapamycin) pathway, sirolimus (Rapamune®) and everolimus (Afinitor®), used in oncology and transplant medicine, now studied for anti-aging and neuroprotective effects.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Emerging Longevity / Neuroregenerative Agents
- Health domains
- neurocognitive
- Evidence grade
- Experimental
- Strength of evidence
- Low
- Cost
- High
- Effort
- Low
- Time commitment
- Low
How to practice Rapamycin / Everolimus
Should only be used under clinical supervision or research protocols. Off-label “longevity” dosing typically 2–6 mg weekly is being studied but not standardized. Regular monitoring of glucose, lipids, and immune markers is essential. Avoid self-administration; consider awaiting results of ongoing human neuroprotection and aging trials. May have disproportionate benefit to APOE4 carriers.
The evidence behind Rapamycin / Everolimus
mTOR inhibition promotes autophagy and reduces protein aggregation and inflammation, mechanisms relevant to neurodegeneration. Animal studies show lifespan extension and improved cognition with low-dose regimens. Human data are limited to small aging and immune function trials; long-term safety and cognitive benefits unproven. Risks include insulin resistance, mouth ulcers, and immune suppression.
More Drugs techniques
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.